AR082941A1 - Metodo para conjugar un polimero hidrosoluble a una porcion de carbohidrato oxidado de una proteina terapeutica - Google Patents
Metodo para conjugar un polimero hidrosoluble a una porcion de carbohidrato oxidado de una proteina terapeuticaInfo
- Publication number
- AR082941A1 AR082941A1 ARP110102758A ARP110102758A AR082941A1 AR 082941 A1 AR082941 A1 AR 082941A1 AR P110102758 A ARP110102758 A AR P110102758A AR P110102758 A ARP110102758 A AR P110102758A AR 082941 A1 AR082941 A1 AR 082941A1
- Authority
- AR
- Argentina
- Prior art keywords
- soluble polymer
- water
- therapeutic protein
- oxidized carbohydrate
- group
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Materiales y métodos para conjugar un polímero hidrosoluble a una porción de carbohidrato oxidado de una proteína terapéutica que comprende poner en contacto la porción de carbohidrato oxidado con un polímero hidrosoluble activado en condiciones que permiten la conjugación. Más específicamente, materiales y métodos antes mencionados, en donde el polímero hidrosoluble contiene un grupo aminooxi activo y en donde se forma un enlace de oxima o hidrazona entre la porción de carbohidrato oxidado y el grupo aminooxi en el polímero hidrosoluble, y en donde la conjugación se realiza en presencia de un catalizador nucleofílico.Reivindicación 1: Un método para conjugar un polímero hidrosoluble a una porción de carbohidrato oxidado de una proteína terapéutica, caracterizado porque comprende poner en contacto la porción de carbohidrato oxidado con un polímero hidrosoluble activado en condiciones que permiten la conjugación; dicho polímero hidrosoluble contiene un grupo aminooxi activo y se selecciona del grupo que consiste en polietilenglicol (PEG), PEG ramificado, PolyPEG® (Warwick Effect Polymers; Coventry, Reino Unido), ácido polisiálico (PSA), almidón, almidón de hidroxialquilo (HAS), almidón de hidroxietilo (HES), carbohidrato, polisacáridos, pululano, quitosano, ácido hialurónico, sulfato de condroitina, sulfato de dermatán, almidón, dextrano, carboximetil-dextrano, óxido de poliaquileno (PAO), polialquilenglicol (PAG), polipropilenglicol (PPG), polioxazolina, poliacriloilmorfolina, alcohol de polivinilo (PVA), policarboxilato, polivinilpirrolidona, polifosfaceno, polioxazolina, polietilen-co-anhídrido de ácido maleico, poliestireno-co-anhídrido de ácido de maleico, poli(1-hidroximetiletilen hidroximetilformal) (PHF), 2-metacriloiloxi-2’-etiltrimetilamoniofosfato (MPC); y dicha porción de carbohidrato oxidado por incubación con un amortiguador que comprende un agente de oxidación seleccionado del grupo que consiste en periodato de sodio (NalO4), tetraacetato de plomo (Pb(OAc)4) y perrutenato de potasio (KRuO4) en donde se forma un enlace de oxima entre la porción de carbohidrato oxidado y el grupo aminooxi activo en el polímero hidrosoluble; y en donde la formación del enlace de oxima se cataliza por medio de un catalizador nucleofílico seleccionado del grupo que consiste en ácido o-aminobenzoico, ácido m-aminobenzoico, ácido p-aminobenzoico, ácido sulfanílico, o-aminobenzamida, o-toluidina, m-toluidina, p-toluidina, o-anisidina, m-anisidina y p-anisidina. Reivindicación 23: El método de acuerdo con cualquiera de las reivindicaciones 2 - 22, caracterizado porque la proteína terapéutica es FIX. Reivindicación 24: El método de acuerdo con cualquiera de las reivindicaciones 2 - 22, caracterizado porque la proteína terapéutica es FVlIa. Reivindicación 25: El método de acuerdo con cualquiera de las reivindicaciones 2 - 22, caracterizado porque la proteína terapéutica es FVII. Reivindicación 53: Una proteína terapéutica modificada, caracterizada porque ha sido producida mediante el método de acuerdo con cualquiera de las reivindicaciones 1 - 52.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36918610P | 2010-07-30 | 2010-07-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR082941A1 true AR082941A1 (es) | 2013-01-23 |
Family
ID=44629987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110102758A AR082941A1 (es) | 2010-07-30 | 2011-07-29 | Metodo para conjugar un polimero hidrosoluble a una porcion de carbohidrato oxidado de una proteina terapeutica |
Country Status (25)
| Country | Link |
|---|---|
| EP (3) | EP2598172B1 (es) |
| JP (7) | JP6325818B2 (es) |
| KR (6) | KR102269494B1 (es) |
| CN (3) | CN103370082A (es) |
| AR (1) | AR082941A1 (es) |
| AU (1) | AU2011282571C1 (es) |
| BR (1) | BR112013001611B1 (es) |
| CA (1) | CA2806684C (es) |
| CY (1) | CY1121943T1 (es) |
| DK (1) | DK2598172T3 (es) |
| EA (2) | EA201691292A1 (es) |
| ES (1) | ES2731626T3 (es) |
| HR (1) | HRP20190990T1 (es) |
| HU (1) | HUE043790T2 (es) |
| LT (1) | LT2598172T (es) |
| MX (1) | MX346271B (es) |
| NZ (1) | NZ605972A (es) |
| PL (1) | PL2598172T3 (es) |
| PT (1) | PT2598172T (es) |
| RS (1) | RS58900B1 (es) |
| SG (2) | SG187171A1 (es) |
| SI (1) | SI2598172T1 (es) |
| TR (1) | TR201908836T4 (es) |
| TW (1) | TWI534152B (es) |
| WO (1) | WO2012016131A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| KR102269494B1 (ko) * | 2010-07-30 | 2021-06-25 | 박스알타 인코퍼레이티드 | 옥심 결합용 친핵성 촉매 |
| NZ612320A (en) | 2010-12-22 | 2015-06-26 | Baxter Healthcare Sa | Materials and methods for conjugating a water soluble fatty acid derivative to a protein |
| EA033469B1 (ru) * | 2012-04-16 | 2019-10-31 | Cantab Biopharmaceuticals Patents Ltd | Подкожное введение конъюгатов факторов крови с полиэтиленгликолем |
| AU2013204754C1 (en) * | 2012-05-16 | 2018-10-11 | Takeda Pharmaceutical Company Limited | Nucleophilic Catalysts for Oxime Linkage |
| MA39711A (fr) * | 2014-04-03 | 2015-10-08 | Nektar Therapeutics | Conjugués d'une fraction d'il-15 et d'un polymère |
| KR20180088727A (ko) * | 2015-12-03 | 2018-08-06 | 박스알타 인코퍼레이티드 | 연장된 반감기 및 감소된 리간드-결합 특성을 가진 인자 viii |
| EP3487538A1 (en) | 2016-07-22 | 2019-05-29 | Nektar Therapeutics | Conjugates of a factor viii moiety having an oxime-containing linkage |
| EP3914711A2 (en) | 2019-01-23 | 2021-12-01 | Regeneron Pharmaceuticals, Inc. | Treatment of ophthalmic conditions with angiopoietin-like 7 (angptl7) inhibitors |
| US11845989B2 (en) | 2019-01-23 | 2023-12-19 | Regeneron Pharmaceuticals, Inc. | Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors |
| CA3210480A1 (en) | 2021-02-26 | 2022-09-01 | Regeneron Pharmaceuticals, Inc. | Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (angptl7) inhibitors |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54113492A (en) | 1978-02-24 | 1979-09-05 | Sanyo Chem Ind Ltd | Preparation of glucoprotein derivative |
| US4356170A (en) | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US5250421A (en) | 1986-01-03 | 1993-10-05 | Genetics Institute, Inc. | Method for producing factor VIII:C-type proteins |
| US5198349A (en) | 1986-01-03 | 1993-03-30 | Genetics Institute, Inc. | Method for producing factor VIII:C and analogs |
| JPH0387173A (ja) | 1987-09-10 | 1991-04-11 | Teijin Ltd | ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体 |
| US5846951A (en) | 1991-06-06 | 1998-12-08 | The School Of Pharmacy, University Of London | Pharmaceutical compositions |
| KR100303872B1 (ko) | 1992-10-02 | 2001-11-22 | 크리스터 발스트룀, 프레드릭 베르그, 하랄트 알름 | 응고인자ⅷ제형을포함하는조성물,이것의제조방법및안정화제로서의계면활성제의사용방법 |
| WO1994028024A1 (en) * | 1993-06-01 | 1994-12-08 | Enzon, Inc. | Carbohydrate-modified polymer conjugates with erythropoietic activity |
| US5621039A (en) | 1993-06-08 | 1997-04-15 | Hallahan; Terrence W. | Factor IX- polymeric conjugates |
| US5574187A (en) * | 1994-10-06 | 1996-11-12 | Uniroyal Chemical Company, Inc. | Process of preparing para substituted phenylamines |
| WO1996040662A2 (en) | 1995-06-07 | 1996-12-19 | Cellpro, Incorporated | Aminooxy-containing linker compounds and their application in conjugates |
| US6531298B2 (en) | 1997-07-21 | 2003-03-11 | The University Of North Carolina At Chapel Hill | Factor IX antihemophilic factor with increased clotting activity |
| US7074878B1 (en) | 1999-12-10 | 2006-07-11 | Harris J Milton | Hydrolytically degradable polymers and hydrogels made therefrom |
| US6413507B1 (en) | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
| ES2256234T3 (es) | 2000-05-16 | 2006-07-16 | Lipoxen Technologies Limited | Derivatizacion de proteinas en solucion acuosa. |
| WO2004099231A2 (en) | 2003-04-09 | 2004-11-18 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
| US7265084B2 (en) | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
| JP4758608B2 (ja) | 2001-11-07 | 2011-08-31 | ネクター セラピューティックス | 分枝ポリマーおよびそれらの結合体 |
| EP1681303B1 (en) | 2002-09-11 | 2013-09-04 | Fresenius Kabi Deutschland GmbH | HASylated polypeptides, especially HASylated erythropoietin |
| KR101045422B1 (ko) | 2002-09-11 | 2011-06-30 | 프레제니우스 카비 도이치란트 게엠베하 | 하이드록시알킬 전분 유도체의 제조 방법 |
| JP4698579B2 (ja) | 2003-04-08 | 2011-06-08 | イエダ リサーチ アンド デベロップメント カンパニー リミテッド | 可逆的ｐｅｇ化薬物 |
| WO2005014655A2 (en) * | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein |
| CN1863549A (zh) * | 2003-08-08 | 2006-11-15 | 费森尤斯卡比德国有限公司 | 通过肟连接基团进行连接的聚合物和蛋白质的缀合物 |
| US20080206182A1 (en) | 2003-08-08 | 2008-08-28 | Fresenius Kabi Deutschland Gmbh | Conjugates of a Polymer and a Protein Linked by an Oxime Group |
| KR101113726B1 (ko) | 2003-08-12 | 2012-02-27 | 리폭센 테크놀로지즈 리미티드 | 단백질 유도 및 컨쥬게이션용 시알산 유도체 |
| US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
| US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
| EP1694274B1 (en) | 2003-12-03 | 2013-04-24 | BioGeneriX AG | Glycopegylated granulocyte colony stimulating factor |
| ES2593318T3 (es) | 2004-08-12 | 2016-12-07 | Lipoxen Technologies Limited | Derivados de ácido siálico |
| US8268967B2 (en) | 2004-09-10 | 2012-09-18 | Novo Nordisk A/S | Glycopegylated interferon α |
| DK1835938T3 (da) | 2004-12-27 | 2013-11-04 | Baxter Int | Polymer-von Willebrand-faktor-konjugater |
| EP1896082B1 (en) | 2005-06-16 | 2012-12-26 | Nektar Therapeutics | Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates |
| US7645860B2 (en) | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
| ES2531934T3 (es) * | 2006-09-01 | 2015-03-20 | Novo Nordisk Health Care Ag | Glicoproteínas modificadas |
| CN101535339B (zh) * | 2006-09-01 | 2014-11-12 | 诺沃-诺迪斯克保健股份有限公司 | 改性糖蛋白 |
| EP2101821B1 (en) | 2006-12-15 | 2014-08-13 | Baxter International Inc. | Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life |
| JPWO2009028573A1 (ja) * | 2007-08-27 | 2010-12-09 | 国立大学法人名古屋大学 | 血液凝固障害におけるリバビリンの利用 |
| GB0908393D0 (en) * | 2009-05-15 | 2009-06-24 | Almac Sciences Scotland Ltd | Labelling method |
| EP2459224B1 (en) * | 2009-07-27 | 2016-06-01 | Baxalta GmbH | Blood coagulation protein conjugates |
| NZ597600A (en) * | 2009-07-27 | 2014-05-30 | Lipoxen Technologies Ltd | Glycopolysialylation of non-blood coagulation proteins |
| US20120164130A1 (en) * | 2009-07-31 | 2012-06-28 | Bayer Healthcare Llc | Modified Factor IX Polypeptides and Uses Thereof |
| KR102269494B1 (ko) * | 2010-07-30 | 2021-06-25 | 박스알타 인코퍼레이티드 | 옥심 결합용 친핵성 촉매 |
-
2011
- 2011-07-29 KR KR1020217007514A patent/KR102269494B1/ko active IP Right Grant
- 2011-07-29 TW TW100126974A patent/TWI534152B/zh active
- 2011-07-29 BR BR112013001611-6A patent/BR112013001611B1/pt active IP Right Grant
- 2011-07-29 SG SG2013005160A patent/SG187171A1/en unknown
- 2011-07-29 EP EP11741727.9A patent/EP2598172B1/en active Active
- 2011-07-29 WO PCT/US2011/045873 patent/WO2012016131A1/en active Application Filing
- 2011-07-29 DK DK11741727.9T patent/DK2598172T3/da active
- 2011-07-29 AU AU2011282571A patent/AU2011282571C1/en active Active
- 2011-07-29 PT PT11741727T patent/PT2598172T/pt unknown
- 2011-07-29 RS RS20190779A patent/RS58900B1/sr unknown
- 2011-07-29 EA EA201691292A patent/EA201691292A1/ru unknown
- 2011-07-29 EA EA201300190A patent/EA025738B9/ru not_active IP Right Cessation
- 2011-07-29 EP EP18208032.5A patent/EP3505186B1/en active Active
- 2011-07-29 JP JP2013521998A patent/JP6325818B2/ja active Active
- 2011-07-29 KR KR1020137004971A patent/KR101969601B1/ko active IP Right Grant
- 2011-07-29 HU HUE11741727A patent/HUE043790T2/hu unknown
- 2011-07-29 NZ NZ60597211A patent/NZ605972A/en unknown
- 2011-07-29 KR KR1020197010071A patent/KR102088852B1/ko active IP Right Grant
- 2011-07-29 SI SI201131742T patent/SI2598172T1/sl unknown
- 2011-07-29 CN CN2011800476351A patent/CN103370082A/zh active Pending
- 2011-07-29 CA CA2806684A patent/CA2806684C/en active Active
- 2011-07-29 ES ES11741727T patent/ES2731626T3/es active Active
- 2011-07-29 KR KR1020207006813A patent/KR102172133B1/ko active IP Right Grant
- 2011-07-29 TR TR2019/08836T patent/TR201908836T4/tr unknown
- 2011-07-29 EP EP21207146.8A patent/EP4023247A1/en active Pending
- 2011-07-29 AR ARP110102758A patent/AR082941A1/es active IP Right Grant
- 2011-07-29 CN CN201810090885.7A patent/CN108079312A/zh active Pending
- 2011-07-29 SG SG10201913078SA patent/SG10201913078SA/en unknown
- 2011-07-29 KR KR1020207030594A patent/KR102229967B1/ko active IP Right Grant
- 2011-07-29 LT LTEP11741727.9T patent/LT2598172T/lt unknown
- 2011-07-29 MX MX2013001261A patent/MX346271B/es active IP Right Grant
- 2011-07-29 CN CN201810089901.0A patent/CN108079311A/zh active Pending
- 2011-07-29 KR KR1020217018874A patent/KR102325780B1/ko active IP Right Grant
- 2011-07-29 PL PL11741727T patent/PL2598172T3/pl unknown
-
2015
- 2015-06-11 JP JP2015118007A patent/JP2015164958A/ja not_active Withdrawn
-
2017
- 2017-05-19 JP JP2017099807A patent/JP2017137358A/ja not_active Withdrawn
-
2019
- 2019-03-28 JP JP2019064337A patent/JP6757823B2/ja active Active
- 2019-03-28 JP JP2019064338A patent/JP2019116501A/ja not_active Withdrawn
- 2019-05-31 HR HRP20190990TT patent/HRP20190990T1/hr unknown
- 2019-06-19 CY CY20191100632T patent/CY1121943T1/el unknown
-
2020
- 2020-11-26 JP JP2020196260A patent/JP7054407B2/ja active Active
-
2021
- 2021-12-27 JP JP2021212106A patent/JP7258999B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR082941A1 (es) | Metodo para conjugar un polimero hidrosoluble a una porcion de carbohidrato oxidado de una proteina terapeutica | |
| AR084576A1 (es) | Materiales y metodos para conjugar un derivado de acido graso hidrosoluble a una proteina | |
| EP2641590B1 (en) | Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration | |
| JP2013500343A5 (es) | ||
| AR077600A1 (es) | Conjugados de proteinas de coagulacion sanguinea | |
| AR071420A1 (es) | Composicion de pastilla para chupar oral que comprende un principio activo de nicotina y procedimiento para fabricarla | |
| Jana et al. | Novel alginate hydrogel core–shell systems for combination delivery of ranitidine HCl and aceclofenac | |
| MXPA05007163A (es) | Derivados polimericos de acido maleamico y sus bioconjugados. | |
| CN109833329B (zh) | 一种透明质酸-多孔纳米硒复合物及其制备方法与应用 | |
| DE602007004212D1 (de) | Hydrogele von polysaccharidmischungen für das gewebe-engineering und als wirkstoffträger | |
| RU2007128946A (ru) | Способные к биодеградации суперабсорбирующие полимерные гидрогели и способ их получения | |
| Manna et al. | Chitosan derivatives as carriers for drug delivery and biomedical applications | |
| NO20084292L (no) | Formulering for legemiddellevering til kolon | |
| Tokatlian et al. | Protease degradable tethers for controlled and cell-mediated release of nanoparticles in 2-and 3-dimensions | |
| RU2016121611A (ru) | Конъюгаты белков свертывания крови | |
| AR080572A1 (es) | Suspensiones de nanoparticulas que contienen polimero de carboxivinilo | |
| RU2751231C2 (ru) | Способ получения хитозана с низким содержанием эндотоксина | |
| JP7339378B2 (ja) | 低エンドトキシンのキトサンの製造方法 | |
| RU2008103037A (ru) | Способ получения глюкозочувствительных полимерных гидрогелей | |
| CN102119932A (zh) | 硅酮水凝胶隐形眼镜用眼科组合物 | |
| EA028186B9 (ru) | Способ конъюгации водорастворимого полимера с терапевтическим белком (варианты) и полученный модифицированный белок | |
| Wang et al. | A tumour microenvironment-responsive polymeric complex for targeted depletion of tumour-associated macrophages (TAMs) | |
| US20180028684A1 (en) | Targeted nanoparticles | |
| AR051944A1 (es) | Suspensiones farmaceuticas exentas de colorantes y metodos relacionados | |
| Cao et al. | Bacteria-adhesive nitric oxide-releasing graphene oxide nanoparticles for MRPA-infected wound healing therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |